Literature DB >> 2522861

The cost of diabetes.

K Gerard1, C Donaldson, A K Maynard.   

Abstract

This paper estimates the cost of diabetes in England and Wales in 1984 to be in excess of 259.5 million pounds. The costing methodology used follows the 'cost of illness' framework. This framework defines three elements for costing: direct, indirect and psychological, although the latter element is left out of the calculation because monetary valuations for this element have never been adequately estimated. Direct costs include resources used to prevent, detect, and treat diabetes. Indirect costs relate to the loss of productive output caused by absenteeism, early retirement, and premature mortality. The estimate which has been obtained is likely to be an underestimate because of the weaknesses and gaps in the data sets. The estimate of the total lost earnings from diabetes varied greatly according to the choice of absentee rate. If there was no significant difference between absenteeism in the diabetic community and the non-diabetic community then the cost of diabetes would be 259.5 million pounds. If on the other hand the diabetic community was prone to three times as much absenteeism as the non-diabetic community then the cost of diabetes would rise to 602.5 million pounds. The costs of diabetes as a subsidiary diagnosis are extremely difficult to identify. They have been estimated in this study to be 86 million pounds but this is thought to be an overestimate. Nevertheless the cost of diabetes is significant and thus the search for more efficient treatment regimens may reduce such costs as well as enhance the quality of life of the patients concerned.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2522861     DOI: 10.1111/j.1464-5491.1989.tb02107.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  17 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

2.  A practical guide for calculating indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

3.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 4.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

5.  Health and healthcare costs and benefits of exercise.

Authors:  J P Nicholl; P Coleman; J E Brazier
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

Review 6.  Economic evaluations of type II diabetes.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

Review 7.  Diabetes mellitus and the St Vincent Declaration. The economic implications.

Authors:  B Leese
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 8.  Primary, secondary and tertiary prevention of non-insulin-dependent diabetes.

Authors:  A Dornhorst; P K Merrin
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

9.  Sickness absence in diabetic employees at a large engineering factory.

Authors:  C J Poole; D Gibbons; I A Calvert
Journal:  Occup Environ Med       Date:  1994-05       Impact factor: 4.402

10.  The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies.

Authors:  Jen Kruger; Alan Brennan
Journal:  Eur J Health Econ       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.